AI USE CASE
Drug Safety Signal Detection Real-World Data
Detect emerging drug safety signals in EHR, claims, and registry data before they reach regulators.
What it is
Machine learning and NLP models mine electronic health records, insurance claims, and patient registries to surface adverse event patterns that clinical trials miss due to population size or duration. Pharmacovigilance teams typically reduce signal review cycle time by 30–50% while increasing the breadth of signals evaluated. Early detection can prevent regulatory enforcement actions and costly post-market withdrawals. Organisations have reported identifying actionable safety signals 6–12 months earlier than traditional spontaneous reporting methods.
Data you need
Longitudinal patient-level data from at least one of: EHR systems, insurance claims databases, or disease registries, with sufficient volume (millions of patient records) and standardised coding (ICD, MedDRA, SNOMED).
Required systems
- data warehouse
- erp
Why it works
- Engage pharmacovigilance experts and medical officers early to define clinically meaningful signal thresholds and review workflows.
- Use standardised medical ontologies (MedDRA, SNOMED CT) and data harmonisation pipelines before model training.
- Implement a transparent, explainable model architecture to satisfy regulatory audit requirements and gain clinician trust.
- Establish a feedback loop where signal reviewers label outcomes to continuously retrain and improve model precision.
How this goes wrong
- Heterogeneous and inconsistently coded source data (ICD versions, free-text notes) leads to high false-positive signal rates that overwhelm reviewers.
- Lack of a validated ground-truth dataset makes it difficult to tune and benchmark model sensitivity versus specificity.
- Regulatory acceptance of algorithmically-generated signals is uncertain without a documented, auditable methodology that satisfies EMA or FDA expectations.
- Siloed data governance across hospital systems or payers prevents access to the longitudinal patient volumes needed for statistical power.
When NOT to do this
Do not attempt this use case if your organisation lacks a centralised, de-identified patient data repository with at least several years of longitudinal history — signal detection on small or fragmented datasets produces noise, not insight.
Vendors to consider
Sources
This use case is part of a larger Data & AI catalog built from 50+ enterprise transformation programs. Take the free diagnostic to see how it ranks against your specific context.